Table 1 Association between GPR39 expression and clinical characteristics of ESCC patients (n = 207)
Clinicopathologic characteristics | GPR39 expression no. (%) | P | |
|---|---|---|---|
| Â | Overexpression | Low expression | Â |
Age (y) | Â | Â | Â |
   ≤60 | 69 (59.5) | 47 (40.5) | 0.735 |
   >60 | 52 (57.1) | 39 (42.9) |  |
Sex | Â | Â | Â |
   Male | 68 (57.6) | 50 (42.4) | 0.887 |
   Female | 53 (59.6) | 36 (40.4) |  |
Tumor location | Â | Â | Â |
   Upper | 22 (53.7) | 19 (46.3) | 0.762 |
   Middle | 82 (59.4) | 56 (40.6) |  |
   Lower | 16 (61.5) | 10 (38.5) |  |
Tumor cell differentiation | Â | Â | Â |
   Well | 15 (53.6) | 13 (46.4) | 0.846 |
   Moderate | 76 (58.9) | 53 (41.1) |  |
   Poor | 30 (60.0) | 20 (40.0) |  |
Tumor invasion (T) | Â | Â | Â |
   T1 | 2 (25) | 6 (75) | 0.085 |
   T2 | 44 (65.7) | 23 (34.3) |  |
   T3 | 75 (57.3) | 56 (42.7) |  |
   T4 | 1 (100) | 0 (0) |  |
Lymph node metastasis (N) | Â | Â | Â |
   N0 | 59 (50.4) | 58 (49.8) | 0.008* |
   N1 | 62 (68.9) | 28 (31.1) |  |
TNM stage | Â | Â | Â |
   I | 1 (14.3) | 6 (85.7) | 0.004* |
   IIa | 57 (52.3) | 52 (47.7) |  |
   IIb | 15 (75.0) | 5 (25.0) |  |
   III-IV | 48 (67.6) | 23 (32.4) |  |